| 产品详情 |
| Edit |   |
|---|
| Product Name | Recombinant Human Double-stranded RNA-specific adenosine deaminase (ADAR), partial |
|---|
| Description | Purity > 90% as determined by SDS-PAGE. MW: 35.6kDa. Partial: 1-176aa. N-terminal 6xHis-SUMO-tagged. Homo sapiens (Human). Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assbly of viral particles. However, high levels of ADAR1 inhibit HDV replication |
|---|
| Size | 100ug |
|---|
| Concentration | n/a |
|---|
| Applications | RUO |
|---|
| Other Names | 136KDA double-stranded RNA-binding protein; p136Interferon-inducible protein 4; IFI-4K88DSRBP |
|---|
| Gene, Accession, CAS # | ADAR, UniProt: P55265 |
|---|
| Catalog # | RPC25840 |
|---|
| Price | |
|---|
| Order / More Info | Recombinant Human Double-stranded RNA-specific adenosine deaminase (ADAR), partial from BIOMATIK |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|